Structure Therapeutics
GPCR | NASDAQ
$18.57
-$1.43 (-7.15%)
At close: Nov 16, 2026, 4:00 PM ET
$18.56
-$0.01 (-0.05%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Structure Therapeutics Company Profile
Company profile explainedCompany Profile
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Raymond C. Stevens | Chief Executive Officer & Director |
| Jun S. Yoon | Co- Founder, Chief Financial Officer & Secretary |
| Yingli Ma | Chief Technology Officer |
| Blai Coll | Chief Medical Officer |
| Bob Gatmaitan | Senior Vice President of People |
| Fang Zhang | Executive Vice President & Head of Biology |
| Hui Lei | Senior Vice President of Chemistry |
| Lani Ibarra | Senior Vice President of Clinical Development Operations |
| Matthew Lang | COO & General Counsel |
| Xichen Lin | Chief Scientific Officer & GM of Structure Shanghai |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 3 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 4 | Filing |
Structure Therapeutics
| Country | United States |
| IPO Date | Feb 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 281 |
| CEO | Raymond C. Stevens |
Contact Details
611 Gateway Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | GPCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001888886 |
| CUSIP Number | 86366E106 |
| ISIN Number | US86366E1064 |
| SIC Code | 2834 |
Recent News
- 7 days ago / globenewswire.comStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- 8 days ago / zacks.comNovo Up 4% in a Month: How Should Investors Approach the Stock Now?
- 28 days ago / globenewswire.comStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
- 1 month ago / zacks.comNovo Down 11% in a Month: How Should Investors Approach the Stock Now?
- 2 months ago / seekingalpha.comStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / seekingalpha.comStructure Therapeutics: The Amylin Data Changes The Math
- 2 months ago / seekingalpha.comStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
- 3 months ago / seekingalpha.comSepterna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
- 5 months ago / seekingalpha.comStructure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 5 months ago / reuters.comStructure's experimental obesity pill shows no signs of liver injury
Add to Watchlist
Select watchlists to add or remove GPCR